Preventive Immunotherapeutics in IBD: RFP
Funds research on immunology-based strategies to prevent postoperative recurrence of IBD, focusing on immune training and innovative cell therapies rather than broad immunosuppression.
Funder: Crohn's and Colitis Foundation
Due Dates: June 30, 2026 (Pre-application) | October 1, 2026 (Full proposal)
Funding Amounts: Up to $900,000 total over 3 years ($300,000/year, contingent on milestones; indirect costs capped at 10%).
Summary: Funds preclinical, translational research on immunology-based strategies to prevent postoperative recurrence of IBD, emphasizing immune training over broad immunosuppression.
Key Information: Both a senior PI and a junior Co-PI are required; international applicants are eligible.
Description
This initiative supports academic research projects aimed at developing immunology-based approaches to prevent postoperative recurrence of inflammatory bowel disease (IBD), with a particular focus on Crohn’s disease. The program seeks to fund preclinical, mechanistic, and translational studies that train or reprogram the immune system to create durable, protective immune states, rather than relying on chronic immune suppression. Research should be grounded in human IBD biology and leverage relevant in vivo or organoid-based models. Areas of interest include antigen-specific immune tolerance, immune-regulatory strategies, and cell therapies such as Tregs, stem cells, and CAR-T. The ultimate goal is to advance next-generation prophylactic immunotherapeutic strategies informed by a deeper understanding of immune memory and regulation.
